Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2016-12-09 Regulatory Filings
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent avslutar pågående fas II-studie med BI-505
Regulatory Filings Classification · 95% confidence The document is a press release dated December 9, 2016, announcing that BioInvent is terminating a Phase II clinical study for BI-505 based on discussions with the FDA, which issued a 'full clinical hold'. It also provides background information on the company's pipeline and contact details. This type of announcement, detailing a significant operational event (study termination due to regulatory action) that is not a standard financial report (like 10-K or IR) or a management change, falls best under general Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if the FDA action is viewed as regulatory enforcement. However, since it is a specific operational update regarding a clinical trial status, and not a formal legal filing or a standard financial release, RNS serves as the most appropriate general regulatory announcement category for significant, non-standard corporate news that doesn't fit the other specific codes. Given the context of regulatory interaction (FDA hold) and operational change, RNS is the best fit as a general regulatory announcement.
2016-12-09 Swedish
BioInvent terminates current BI-505 Phase II study
Legal Proceedings Report Classification · 99% confidence The document is explicitly labeled as a "PRESS RELEASE" dated December 9, 2016. It announces a specific corporate action: the termination of a clinical Phase II study (BI-505) following a regulatory hold by the FDA. This type of announcement, which communicates material, non-financial operational news to the market immediately, fits best under the general category for regulatory announcements that are not specifically earnings, dividend, or director dealing reports. Since it is a material announcement that doesn't fit the more specific categories (like ER, DIV, DIRS, or LTR), the most appropriate classification is the general regulatory filing/announcement category, RNS (Regulatory Filings). The document length is short (2906 chars), but it is the primary announcement itself, not an announcement *about* another report, so RPA is less suitable than RNS for this type of operational news release.
2016-12-09 English
BioInvent rapporterar ”clinical hold” för fas II-studie med BI-505
Legal Proceedings Report Classification · 95% confidence The document is a press release dated November 8, 2016, announcing that the FDA has placed a 'clinical hold' on BioInvent's Phase II study for BI-505 due to a cardiopulmonary event. This is a specific, material event concerning ongoing clinical trials and regulatory interaction. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS). It specifically details a legal/regulatory matter impacting operations, which aligns best with the 'Legal Proceedings Report' (LTR) category, as a clinical hold is a significant regulatory action/issue affecting the company's development pipeline. Given the short length and nature as an announcement, it is not a comprehensive report, but the content is highly specific to a regulatory/legal matter.
2016-11-08 Swedish
BioInvent reports clinical hold on BI-505 phase II study
Legal Proceedings Report Classification · 99% confidence The document is a press release dated November 8, 2016, announcing that the FDA has placed a clinical hold on BioInvent's Phase II study for BI-505 due to an adverse event. This is a specific, material event concerning ongoing clinical trials and regulatory interaction. It is not a full financial report (10-K or IR), an earnings release (ER), a management discussion (MDA), or a formal proxy/governance document. It details a significant legal/regulatory event impacting operations, which aligns best with the 'Legal Proceedings Report' (LTR) category, as clinical holds often involve regulatory actions and legal/safety implications, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the specific nature of the FDA action impacting a clinical trial, LTR is a strong fit, as it relates to significant legal/regulatory matters involving the company's operations. Since it is a direct announcement of a regulatory action/hold, LTR is more specific than the general RNS fallback.
2016-11-08 English
Major Shareholding Notification 2016
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding for a specific holder ('Dharminder Chahal') in an issuer ('BioInvent International Aktiebolag'). It quantifies the 'Shares' and 'Voting rights' before and after a 'Sell' transaction, noting the resulting percentage (4.9%) and the date of the transaction (04/11/2016). This structure perfectly matches the definition of a Major Shareholding Notification, which tracks when an investor crosses ownership thresholds. This corresponds to the filing code MRQ.
2016-11-07 English
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'delårsrapport' (interim report) for BioInvent covering the period from January 1 to September 30, 2016. It contains detailed financial statements, including income statements, cash flow data, and management commentary on business performance and clinical trial progress. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2016
2016-10-25 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.